Related by context. All words. (Click for frequent words.) 68 Azedra 67 IMGN# 66 Bezielle 66 CBLC# 66 CR# vcMMAE 66 alvespimycin 65 HGS ETR1 65 phase IIa clinical 65 CRLX# 65 HuMax EGFr 65 obatoclax 65 tanespimycin 65 IMA# 64 axitinib 64 CoFactor 64 PXD# 64 PROCHYMAL 64 GAP #B# 64 cilengitide 64 Ceflatonin 64 ELACYT 64 ganetespib 64 Reolysin 64 preclinically 64 ZYBRESTAT 64 Alpharadin 64 Tarvacin 64 Cotara R 63 picoplatin 63 ThermoDox 63 PSMA ADC 63 Virulizin ® 63 glufosfamide 63 ZACTIMA 63 HGS# 63 phase IIb clinical 63 teriflunomide 63 AP# [003] 63 PEG SN# 63 Vicinium TM 63 enzastaurin 63 ProSavin 63 farletuzumab 63 AEG# 63 Exherin TM 63 BrachySil TM 63 CA4P 63 rindopepimut 63 ALN VSP 63 INT# [002] 62 XmAb# 62 heavily pretreated patients 62 INCB# [001] 62 IRX 2 62 bavituximab 62 TG# [003] 62 CERE 62 SNT MC# 62 sunitinib malate 62 OncoVEX GM CSF 62 Chemophase 62 ixabepilone 62 OXi# 62 Xanafide 62 romidepsin 62 sapacitabine 62 indibulin 62 Aplidin 62 Phase 1b trial 62 perifosine 62 Sym# 62 resminostat 62 AeroLEF TM 62 Phase 2a trial 62 ARIKACE 62 Imprime PGG 62 YONDELIS 62 HuLuc# 62 CIMZIA TM 62 Proxinium TM 62 pomalidomide 62 PROSTVAC TM 62 Virulizin R 62 REOLYSIN ® 62 huC# DM4 62 HER2 positive metastatic breast 62 phase Ib 61 GRN# 61 BRIM2 61 neratinib 61 eniluracil 61 nab paclitaxel 61 abiraterone acetate 61 GVAX 61 talactoferrin 61 HQK 61 ENMD # 61 Carfilzomib 61 elacytarabine 61 MYDICAR ® 61 EFAPROXYN 61 MGd 61 Ceplene/IL-2 61 CLORETAZINE TM VNP#M 61 omega interferon 61 vorinostat 61 dose cohorts 61 liposomal formulation 61 favorable pharmacokinetic profile 61 Phase 1b 61 forodesine 61 DCVax ® 61 antiangiogenic therapy 61 lorvotuzumab mertansine 61 Phase #/#a trial 61 Marqibo 61 CCX# 61 recurrent glioblastoma 61 pertuzumab 61 Anthim 61 Vandetanib 61 EndoTAG TM -1 61 Archexin 61 OHR/AVR# 61 ADVEXIN 61 deforolimus 61 brivaracetam 61 afatinib 61 Neuradiab 61 anti leukemic 61 tipranavir 61 gemcitabine chemotherapy 61 EVIZON 61 recurrent glioma 61 CIMZIA ™ 61 lumiliximab 61 recurrent NSCLC 61 Traficet EN 61 Phase Ib study 60 Curaxin 60 lintuzumab 60 Advexin 60 Phase Ib II 60 PLX cells 60 anti angiogenic therapy 60 pralatrexate 60 tesmilifene 60 oral ridaforolimus 60 oral prodrug 60 Phase 2a 60 IRESSA 60 paclitaxel poliglumex 60 orally dosed 60 GAMMAGARD 60 DAVANAT 60 APOPTONE 60 INGN 60 anti EGFR antibody 60 ofatumumab 60 ESBA# 60 IL# PE#QQR 60 riociguat 60 Tyrima 60 OncoGel 60 trabedersen 60 Aeroquin 60 tubulin inhibitor 60 Alocrest 60 ProLindac 60 LY# [003] 60 amrubicin 60 VIDAZA 60 Amplimexon 60 Cethrin 60 ISIS # 60 olaparib 60 FOLOTYN 60 phase IIb study 60 blinatumomab 60 Delcath PHP System 60 samalizumab 60 metastatic melanoma 60 seliciclib 60 Phase IIa clinical 60 castration resistant prostate cancer 60 Gliadel Wafer 60 elotuzumab 60 Phase Ib 60 Tesmilifene 60 BNC# 60 cediranib 60 Quinamed 60 ToGA 60 Rexin G 60 velafermin 60 heavily pretreated 60 Cotara ® 60 oral FTY# 60 Xcytrin 60 liver metastases 60 Enzastaurin 60 teduglutide 60 CYT# potent vascular disrupting 60 IIa trial 60 velafermin belinostat 60 rALLy trial 60 Phase IIIb clinical 60 Omacetaxine 60 carfilzomib 60 nanopharmaceutical 60 ThermoDox ® 60 NP2 Enkephalin 60 CYT# 59 Azixa 59 decitabine 59 ponatinib 59 recurrent GBM 59 JAK2 inhibitor 59 dose escalation phase 59 Phase Ib clinical 59 vandetanib 59 Trastuzumab 59 ALN TTR 59 Allovectin 7 ® 59 EOquin 59 Onconase 59 PEP# [003] 59 Amrubicin 59 isoform selective 59 Zybrestat 59 imetelstat 59 MultiStem 59 recurrent glioblastoma multiforme 59 lapatinib Tykerb 59 fosbretabulin 59 CINTREDEKIN BESUDOTOX 59 omacetaxine 59 phase IIb trial 59 antitumor 59 OncoVEX 59 MEK inhibitors 59 JAK inhibitor 59 phase IIb 59 elesclomol 59 #I TM# 59 TACI Ig 59 oral Xeloda 59 vascular disrupting agent 59 XL# [003] 59 DACH platinum 59 relapsed multiple myeloma 59 tafamidis 59 Phase 1a clinical 59 HRPC 59 paclitaxel Taxol ® 59 Symadex 59 VNP#M 59 Panzem R NCD 59 PRX# 59 Campath alemtuzumab 59 pharmacokinetic PK study 59 Nanobody 59 advanced carcinoid 59 pazopanib 59 IMC A# 59 PROSTVAC VF 59 DAVANAT R 59 Tarvacin TM 59 Curaxin CBLC# 59 IMC #B 59 mapatumumab 59 DCVax 59 triphendiol 59 Phase #b/#a 59 PEG Interferon lambda 59 dose escalation 59 AKT inhibitor 59 hematological cancers 59 milatuzumab 59 ularitide 59 huN# DM1 59 Insegia 59 Aplidin R 59 ATL# [001] 59 relapsing multiple sclerosis 59 targeting CD# 59 EOquin TM 59 lupus nephritis 59 DXL# 59 custirsen 59 HGS ETR2 59 Hsp# inhibitor 59 anti amnesic 59 Tanespimycin 59 Phase 2b trial 59 registrational 59 GALNS 59 CBLB# 59 Removab 59 depsipeptide 59 IMP# 59 rFIXFc 59 methylnaltrexone 59 Hsp# inhibition 59 Panzem 59 Triolex 58 Phase #b/#a clinical 58 pediatric malignancies 58 vismodegib 58 metaglidasen 58 bevacizumab Avastin 58 metastatic hormone refractory 58 investigational therapies 58 Irinotecan 58 TroVax 58 TELCYTA 58 standard chemotherapy regimen 58 MAGE A3 ASCI 58 molecularly targeted 58 Troxatyl 58 antitumor activity 58 ThermoDox R 58 Ceflatonin R 58 Cloretazine R VNP#M 58 orally bioavailable 58 Vidofludimus 58 SUTENT 58 CTAP# Capsules 58 Allovectin 7 58 doxorubicin Transdrug ® 58 HDAC Inhibitor 58 TRIOLEX 58 AQ4N 58 ThGRF 58 immatics 58 DR Cysteamine 58 FTY# 58 ADVANCE PD 58 HuMax CD4 58 Pertuzumab 58 DP b# 58 Tesetaxel 58 Urocidin 58 vidofludimus 58 relapsed refractory multiple myeloma 58 Pimavanserin 58 #D#C# 58 gefitinib Iressa 58 evaluating tivozanib 58 eculizumab 58 refractory CLL 58 recurrent glioblastoma multiforme GBM 58 hA# 58 SAR# [004] 58 tgAAC# 58 BCIRG 58 ospemifene 58 p# biomarker 58 tolerated dose MTD 58 adecatumumab 58 BAY #-# 58 Aurexis 58 HuMax CD# 58 DCVax Brain 58 glioblastoma multiforme GBM 58 refractory metastatic 58 Allovectin 7 R 58 Revimmune 58 histone deacetylase HDAC inhibitor 58 trastuzumab DM1 T DM1 58 SUCCEED trial 58 docetaxel chemotherapy 58 subcutaneous formulation 58 velaglucerase alfa 58 estramustine 58 Panzem NCD 58 ara C 58 Valortim 58 DCVax R 58 RGB # 58 BRAF inhibitor 58 Interferon alpha 58 ruboxistaurin 58 dose escalation trial 58 docetaxel Taxotere R 58 Phase #/#a 58 sunitinib 58 ReN# 58 Viprinex 58 CORT # 58 ATL/TV# 58 ADAGIO study 58 satraplatin 58 SIR Spheres 58 rALLy clinical trial 58 NTx TM -# 58 ZD# [001] 58 oral picoplatin 58 bendamustine 58 neoadjuvant chemotherapy 58 Cloretazine ® 58 regorafenib 58 cisplatin chemotherapy 58 mouse xenograft models 58 R#/MEM # 58 Kahalalide F 58 radiation sensitizer 58 crizotinib PF # 58 azacitidine 58 ANAVEX #-# [001] 58 tramiprosate Alzhemed TM 58 carboplatin paclitaxel 58 canakinumab 58 Spheramine 58 rilonacept 58 radiolabeled TM# 58 LUX Lung 58 PF # [001] 58 MORAb 58 ataluren 58 PCK# 58 Pemetrexed 58 HORIZONS AMI trial 58 GRN#L 58 immune modulating 57 Intravenous CP 57 Litx 57 pegylated liposomal doxorubicin 57 relapsed MM 57 receptor tyrosine kinase inhibitor 57 metastatic CRC 57 maximally tolerated dose 57 Prochymal 57 favorable tolerability 57 #ME# 57 thymalfasin 57 multicenter Phase 57 xenograft models 57 INCB# [002] 57 multicenter Phase II 57 Hepatocellular Carcinoma HCC 57 TriRima 57 phenoxodiol 57 phase IIa 57 Targretin 57 NEUMUNE 57 Exelixis XL# 57 DCVax R Brain 57 pharmacodynamic PD 57 NEUGENE 57 Resten NG 57 Phase 2a clinical 57 antiangiogenic activity 57 biliary tract cancer 57 recurrent GBM patients 57 pediatric acute lymphoblastic 57 OMAPRO 57 gemcitabine carboplatin 57 CLARITY study 57 DCVax ® Brain 57 temozolomide 57 Atiprimod 57 Taxol ® 57 Cloretazine 57 valopicitabine 57 ANG# 57 KNS # 57 BEXXAR 57 telaprevir dosed 57 PLX# 57 Tarceva TM 57 atacicept 57 relapsed SCLC 57 mertansine 57 zanolimumab 57 hematologic malignancies 57 BrachySil 57 Doxorubicin 57 angiogenesis inhibition 57 ErbB2 positive 57 cannabinor 57 IND submission 57 OPAXIO 57 CGEN # 57 rBChE 57 paclitaxel Taxol R 57 lenalidomide Revlimid R 57 antiangiogenic 57 Temsirolimus 57 trial evaluating PRX# 57 DU #b 57 trodusquemine 57 ORMD 57 anticancer compound 57 docetaxel Taxotere ® 57 GFT# 57 chemoradiotherapy 57 radiotherapeutic 57 BRIM3 57 RRMS patients 57 ibandronate 57 JAK inhibitors 57 CEQ# 57 Nicole Onetto MD 57 gemcitabine Gemzar ® 57 telomerase inhibition 57 Bendavia 57 refractory acute myeloid 57 tesetaxel 57 protein kinase inhibitor 57 CCR9 antagonist 57 antitumor effect 57 TELINTRA 57 zalutumumab 57 galiximab 57 davunetide intranasal AL 57 Pazopanib 57 Pirfenidone 57 dirucotide 57 tolerability profile 57 MGCD# [001] 57 metastatic colorectal 57 PRT# 57 clinical pharmacology studies 57 Phase 2b study 57 Cloretazine R 57 TG# [001] 57 PRTX 57 Asentar 57 ONCONASE 57 pharmacokinetic PK 57 Gefitinib 57 oral gallium 57 TRISENOX 57 chemotherapeutic drug 57 ZOLINZA 57 oral deforolimus 57 orBec 57 Fodosine 57 Ophena TM 57 gastrointestinal stromal tumors 57 TOLAMBA 57 PS# [001] 57 preclinical efficacy 57 MAXY G# 57 GLYX 57 temsirolimus 57 nonclinical studies 57 Phase 1b clinical 57 sorafenib tablets 57 Phase 1b clinical trials 57 pradefovir 57 vemurafenib 57 proteasome inhibitor bortezomib 57 Squalamine 57 Dacogen injection 57 nitazoxanide 57 TTF Therapy 57 microwave hyperthermia 57 relapsed ovarian cancer 57 refractory multiple myeloma 57 ulimorelin 57 angiogenesis inhibitor 57 TMC# [002] 57 NVA# 57 bafetinib 57 PolyActive ® 57 pegfilgrastim 57 durable remissions 57 SPIRIT IV 57 EDEMA3 trial 57 GRASPA ® 57 Mylotarg 57 pancreatic adenocarcinoma 57 therapeutic monoclonal antibody 57 rNAPc2 57 melphalan prednisone 57 VEGF Trap 57 MAP# 57 oral antiviral 57 trastuzumab Herceptin 57 rFVIIIFc 57 monoclonal antibody conjugated 57 entinostat 57 NGX# 57 prostate cancer mCRPC 57 dose cohort 57 ASA# 57 RLY# 57 C1 INH 57 elagolix 57 ANAVEX #-# [003] 57 NLX P# 57 refractory indolent non 57 evaluable patients 57 Elotuzumab 57 torezolid phosphate 57 Amigal 57 multi kinase inhibitor 57 CANCIDAS 57 Triapine R 57 XYOTAX TM 57 AAG geldanamycin analog 57 Abiraterone acetate 57 randomized controlled Phase 57 ELND# 57 metastatic renal cell carcinoma 57 DermaVir Patch 57 EndoTAG TM 57 leukemia AML 57 ALN TTR# 57 placebo controlled Phase 57 systemically administered 57 sipuleucel T 57 cetuximab Erbitux ® 57 prospectively defined 57 Phase 2b clinical 57 Glufosfamide 57 anticancer agents 57 microplasmin 57 LBH# 57 peptide antigens 57 prostate cancer CRPC 57 MOZOBIL 57 randomized Phase III 57 PNT# 57 anticancer 57 recurrent malignant glioma 57 registrational trial 57 Triapine 57 Phase IIa trial 57 locoregional disease 57 GSK# [001] 57 oblimersen 57 solid tumors 57 Neuradiab TM 57 OMP #M# 56 ozarelix 56 Seliciclib 56 Blinatumomab 56 brain metastases 56 Golimumab 56 PKC# 56 Ophena 56 TOCOSOL Paclitaxel 56 Catena ® 56 Angiolix 56 rHuPH# 56 Apoptone 56 EGFRvIII 56 Phase 2b 56 CTCE 56 Lenocta 56 Tumour Vascular Disrupting Agent 56 Phase IIB 56 eribulin mesylate 56 pan HDAC inhibitor 56 resolvin 56 dacetuzumab 56 viral kinetic 56 Phase IIa trials 56 BIBW 56 HCV protease inhibitor 56 AZILECT ® 56 cyclophosphamide chemotherapy 56 tremelimumab 56 optimal dosing 56 zoledronic acid 56 nimotuzumab 56 bortezomib Velcade R 56 Neupogen ® 56 SERCA2a 56 FOLOTYN ® 56 cytokine refractory 56 davunetide 56 AVADO 56 docetaxel 56 PERSEUS 56 RG# [001] 56 OvaRex R 56 cytotoxic agents 56 drug GAP #B# 56 BZL# 56 ruxolitinib 56 Onrigin 56 TNFerade 56 XL# SAR# 56 blinded randomized placebo controlled 56 dosing cohort 56 fenretinide 56 cortical stimulation 56 leading oral taxane 56 Phase III psoriasis 56 Perifosine 56 liposomal doxorubicin 56 COPAXONE R 56 dacarbazine chemotherapy 56 CD# antibody [001] 56 ILLUMINATE 56 Arranon 56 PLX PAD 56 THR beta agonist 56 PROMACTA 56 Nasulin 56 confirmatory Phase III 56 VELCADE 56 intranasal delivery 56 budesonide foam 56 sorafenib Nexavar 56 LHRH antagonists 56 veltuzumab 56 PLK1 SNALP 56 rALLy 56 radezolid 56 synthetic retinoid 56 MLN# 56 plus dexamethasone 56 EDEMA3 56 mCRC patients 56 LymphoStat B 56 abiraterone 56 Afatinib 56 rhIL 7 56 NeoLipid R 56 ACZ# 56 OMNARIS HFA 56 iSONEP 56 bevacizumab Avastin ® 56 PROVENGE 56 ZFP TF 56 FTY# fingolimod 56 BEMA TM Fentanyl 56 GW# [003] 56 flavopiridol 56 immunomodulatory 56 voreloxin 56 Annamycin 56 Alzhemed TM 56 varespladib 56 CCR9 56 Trofex 56 Genz # 56 PROSTVAC ® 56 metastatic malignant melanoma 56 DepoVax 56 dosage regimens 56 Epratuzumab 56 PEG PAL 56 TASQ 56 Cimzia TM 56 LE DT 56 YONDELIS R 56 bortezomib 56 belinostat 56 topotecan 56 EndoTAGTM 1 56 thetreatment 56 radiolabeled monoclonal antibody 56 Actilon 56 bortezomib Velcade 56 Telintra 56 T DM1 56 trastuzumab DM1 56 eTag assays 56 papillary renal cell carcinoma 56 PANVAC VF 56 novel VDA molecule 56 anti angiogenic agents 56 rxRNA 56 targeted radiotherapeutic 56 Neulasta ® 56 subcutaneous SC 56 atrasentan 56 tamibarotene 56 radiolabeled 56 PNP inhibitor 56 colorectal liver metastases 56 unresectable tumors 56 SPC# [001] 56 trabectedin 56 darinaparsin 56 imexon 56 Xcellerated T Cells 56 PKCi 56 taxane refractory 56 AEZS 56 glioma cells 56 StemEx R 56 Prostate AdenoCarcinoma Treatment 56 HCD# [002] 56 eltrombopag 56 randomized Phase 2b 56 JAK3 56 luteinizing hormone releasing 56 GRNVAC1 56 ON #.Na 56 ARRY 56 RAPAFLO 56 docetaxel Taxotere 56 TREANDA 56 BiovaxID 56 intratumoral injection 56 PHX# 56 PI3K/Akt pathway inhibitor 56 ABSORB trial 56 talabostat 56 ISF# 56 adult chronic ITP 56 Vectibix monotherapy 56 Phase IIb clinical 56 Debio 56 SUTENT ® 56 Tavocept 56 GVAX ® 56 gemcitabine cisplatin 56 paclitaxel Taxol 56 NO# [002] 56 RDEA# 56 HspE7 56 BAL# [002] 56 Phase IIb trials 56 palifosfamide 56 viral kinetics 56 indolent NHL 56 cancer immunotherapies 56 MEK inhibitor RDEA# 56 L BLP# 56 panitumumab 56 complete cytogenetic response 56 visilizumab 56 placebo controlled clinical 56 metastatic castration resistant 56 GED aPC 56 TYKERB 56 Phase 1a 56 Cytoxan 56 preclinical studies 56 antisense drug 56 Aptivus ® 56 metastatic RCC 56 PEGylated interferon 56 plasma kallikrein inhibitor 56 ASONEP 56 A3 adenosine receptor 56 chimeric monoclonal antibody 56 hyperthermia therapy 56 Harry Palmin President 56 metastatic bladder 56 MYCAMINE 56 Radilex 56 Restanza 56 nucleoside analog 56 BioNumerik 56 Genasense ® 56 Lymphoseek ® 56 OvaRex ® MAb 56 Hizentra 56 neoadjuvant therapy 55 double blinded placebo 55 NOX E# 55 colorectal cancer liver metastases 55 Halaven 55 Genasense ® oblimersen 55 celgosivir 55 Sphingomab 55 Nimotuzumab 55 INC# 55 sorafenib Nexavar ® 55 laquinimod 55 octreotide 55 lymphoma CTCL 55 satraplatin Phase 55 KRAS wild 55 Valortim R 55 Platinol ® cisplatin 55 mGluR2 NAM 55 Vascugel 55 Pivotal Phase III 55 darapladib 55 Daclizumab 55 Abiraterone 55 Serdaxin 55 Gemzar ® 55 Guanilib 55 VAPRISOL 55 IVIg 55 Arsenic trioxide 55 Dasatinib 55 MyVax R 55 Alfimeprase 55 VA# [002] 55 miglustat 55 apremilast 55 Gleevec resistant 55 GLPG# 55 multicenter trials 55 carcinoid 55 NABTT 55 Vitaxin 55 HCV protease inhibitors 55 HER2 positive cancers 55 randomized discontinuation trial 55 denufosol 55 mg/m2 dose 55 orally administered inhibitor 55 inhibit metastasis 55 MBP# [001] 55 UPLYSO 55 Vidaza azacitidine 55 Phase IIb clinical trials 55 Romidepsin 55 intravenous bisphosphonates 55 anticancer agent 55 HGS ETR1 mapatumumab 55 pharmacokinetic profile 55 motesanib 55 multicenter Phase III 55 MKC# MKC# PP 55 arbaclofen 55 KRN# 55 dasatinib 55 Inhaled AAT 55 XL# XL# XL# 55 MGCD# [002] 55 antithrombotic 55 vinca alkaloid 55 cinacalcet 55 MYDICAR 55 chemotherapeutic regimen 55 LCP Tacro 55 antitumor effects 55 SRT# [003] 55 ipilimumab 55 tezampanel 55 MERLIN TIMI 55 humanised antibody 55 omacetaxine mepesuccinate 55 dose limiting toxicities 55 clofarabine 55 CytoFabTM 55 CYC# 55 Solazed 55 TEMODAL 55 RAV# 55 OMP #R# 55 phase 2a 55 SIR Spheres microspheres 55 EGFR TKI 55 neuroprotective properties 55 IgG1 antibody 55 XGEVA 55 investigational compound 55 concurrent chemoradiation 55 KRAS status 55 MabCampath 55 oncolytic virus 55 Plicera 55 taxane chemotherapy 55 AVOREN 55 p# inhibitor 55 Gabapentin GR 55 EchoCRT 55 cabozantinib 55 tezampanel NGX# 55 Acute Ischemic Stroke 55 gemcitabine 55 cysteamine 55 potent antiproliferative 55 AMD# [003] 55 SCCHN 55 vascular disrupting agents 55 OZURDEX ® 55 melphalan 55 Phenoptin 55 Microplasmin 55 cisplatin gemcitabine 55 Tamibarotene 55 cariprazine 55 lixisenatide 55 DAPT 55 Phase IIb III 55 Taxotere R 55 Melphalan 55 CTA# Injection 55 GMX# 55 Dacogen decitabine 55 imatinib therapy 55 chemotherapeutics 55 mipomersen 55 DAVANAT ® 55 otelixizumab 55 gastrointestinal stromal tumors GIST 55 ONCONASE R 55 bortezomib Velcade ® 55 Betaferon ® 55 prospective multicenter 55 pivotal Phase III 55 Phase Ia 55 octreotide LAR